Final results of a phase I study of the Heat Shock Protein 90 inhibitor Alvespimycin (17-DMAG) in patients with advanced, solid tumours


Session type:

Simon Pacey1, Richard Wilson4, Mike Walton1, Martin Eatock4, Anna Zetterlund1, Hendrik-Tobias Arkenau2, Belle Roels3, Florence Raynaud1, Jooern Ang2, Samantha Costigan1, David Olmos2, Rebecca Gallagher4, Paul Workman1, Ian Judson1

1The Institute of Cancer Research, Sutton, UK, 2The Royal Marsden Hospital, Sutton, UK, 3Cancer Research UK, London, UK, 4N. Ireland Cancer Clinical Trials Unit, Belfast, UK


Method and Results

Alvespimycin [17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)] inhibits N-terminal ATPase activity of Heat Shock Protein 90 (HSP90).